Inhibrx - About the company
Inhibrx is an acquired company based in Solana Beach (United States), founded in 2009 by Quinn Deveraux. It operates as an Antibody-based immunotherapeutics for cancer and infectious diseases. Inhibrx has raised $469M in funding from Viking Global Investors, with last known valuation of $*****. The company has 5001 active competitors, including 1219 funded and 942 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, AbbVie and Amgen.
Company Details
Antibody-based immunotherapeutics for cancer and infectious diseases. it has proprietary platforms that enable fit-for-function bio-therapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. Its product pipeline includes INBRX-109 an engineered tetravalent sdAb-based therapeutic candidate to induce tumor selective programmed cell death, and INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 to treat locally advanced or metastatic solid tumors.
- Website
- inhibrx.com
- Email ID
- *****@inhibrx.com
- Registered Address
- San Diego, California
Key Metrics
Founded Year
2009
Location
Solana Beach, United States
Stage
Acquired
Total Funding
$469M in 12 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jan 23, 2024
Investors
Ranked
377th among 5001 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2023
Employee Count
112 as on May 31, 2026
Exit Details
Acquired by Sanofi (Jan 23, 2024)
Legal entities associated with Inhibrx
Inhibrx is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
INHIBRX, INC. CIN: 824257312 , United States, Active | Dec 26, 999 | $1M - $10M (As on Dec 31, 2023) | 159 (As on Dec 31, 2023) | - |
Inhibrx's acquisition details
Click here to take a look at Inhibrx's acquisition in detail
Sign up to download Inhibrx's company profile
Inhibrx's funding and investors
Inhibrx has raised a total funding of $469M over 12 rounds. Its first funding round was on Apr 09, 2015. Its latest funding round was a Grant (prize money) round on Mar 10, 2025 for $*****. 1 investor participated in its latest round. Inhibrx has 10 institutional investors.
Here is the list of recent funding rounds of Inhibrx:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 10, 2025 | 6463617 | Grant (prize money) | 1112490 | 3422806 | 4477826 | 3610188 |
Sep 13, 2023 | 7871174 | Post IPO | 7534709 | 2119915 | 6108898 | 6936808 |
Feb 15, 2021 | 6243840 | Grant (prize money) | 1899095 | 2420817 | 7763319 |
Access funding benchmarks and valuations. Sign up today!View details of Inhibrx's funding rounds and investors
Inhibrx's founders and board of directors
Founder? Claim ProfileThe founders of Inhibrx is Quinn Deveraux.
Here are the details of Inhibrx's key team members:
- Quinn Deveraux: Founder and EVP of early research of Inhibrx.
- Mark Lappe: CEO of Inhibrx.
View details of Inhibrx's Founder profiles and Board Members
Inhibrx's employee count trend
Inhibrx has 112 employees as of May 26. Here is Inhibrx's employee count trend over the years:
Uncover Inhibrx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Inhibrx's Competitors and alternates
Top competitors of Inhibrx include Jazz Pharmaceuticals, AbbVie and Amgen. Here is the list of Top 10 competitors of Inhibrx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
3rd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 81/100 | |
4th | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 80/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 79/100 | |
6th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
7th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
8th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 73/100 | |
9th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
10th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
377th | Inhibrx 2009, Solana Beach (United States), Acquired | Antibody-based immunotherapeutics for cancer and infectious diseases | $469M | 56/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Inhibrx's competitors? Click here to see the top ones
Inhibrx's Investments and acquisitions
Inhibrx has made no investments or acquisitions yet.
Reports related to Inhibrx
Here is the latest report on Inhibrx's geography:
News related to Inhibrx
Filter this listMedia has covered Inhibrx for a total of 12 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.
•
•
Inhibrx Biosciences Announces Positive Interim Results from HexAgon Trial for Head and Neck Cancerclinicaltrialsarena.com•May 12, 2026•Inhibrx
•
•
•
•
Foresite Capital Management VI LLC Makes New Investment in Spyre Therapeutics, Inc. $SYREMarketBeat•Nov 26, 2025•Spyre Therapeutics, Foresite Capital, Franklin Templeton Investments, and 1 other
•
•
Inhibrx Biosciences' stock soars on chondrosarcoma Phase II victoryclinicaltrialsarena.com•Oct 24, 2025•Inhibrx, Servier Pharmaceuticals, Bristol-Myers Squibb, Sanofi
•
•
XTX Topco Ltd Makes New Investment in Inhibrx Biosciences, Inc. (NASDAQ:INBX)MarketBeat•Aug 14, 2025•Inhibrx
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Inhibrx
Explore our recently published companies
- Wisdom Square Technologies - New Hyde Park based, 2008 founded, Unfunded company
- Fruverpack - Almoradi based, 1992 founded, Unfunded company
- AERA - Bouxwiller based, 1979 founded, Unfunded company
- Divine Hindu - Ujjain based, 2023 founded, Unfunded company
- Globaldigitalpartner.com - 2013 founded, Unfunded company
- OROK - Bourgoin Jallieu based, 2018 founded, Deadpooled company
